Join us for a Radiology Business webinar and live Q&A on Tuesday, April 21, with leaders from this seven-center imaging group and a veteran financial expert.
Almost 15% of more than 5,500 U.S. adults—representing around 14 million individuals—have skipped a doctor visit after feeling satisfied enough with health advice they received from AI.
Demonstrated cost-effectiveness is a highly motivating factor in getting healthcare workers to adopt measures for preventing and controlling healthcare-associated infections.
The product, which is offered within Elucid’s novel Plaque-IQ software suite, allows physicians to analyze lesion composition and plaque burden across any vessel.
The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.
The deal includes an upfront payment of $20 million. Stereotaxis could pay up to an additional $25 million if certain regulatory and commercial milestones are met.
ACR and 10 other medical societies filed a “friend of the court” brief in an ongoing lawsuit against the National Institutes of Health, HHS and their leaders.
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions.
Workforce solutions could include regional on-call pools serving multiple facilities and cross-training vascular surgeons and interventional cardiologists on select procedures.
RSNA and several other industry societies have shared a new expert consensus document on the significant value of cardiac CT. Echo remains an effective first-line imaging option, the groups wrote, but CT can make a big impact as well.
Join us for a Radiology Business webinar and live Q&A on Tuesday, April 21, with leaders from this seven-center imaging group and a veteran financial expert.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
